Catheter Complications Clinical Trial
— CLiCKOfficial title:
Control of Line Complications With KiteLock (CLiCK) in the Critical Care Unit
NCT number | NCT04548713 |
Other study ID # | 0001 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 22, 2022 |
Est. completion date | December 31, 2024 |
Verified date | April 2024 |
Source | Fraser Health |
Contact | Marlena Ornowska |
Phone | 2363326575 |
mornowsk[@]sfu.ca | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Insertion of a central venous access device (CVAD) allows clinicians to easily access the circulation of a patient to administer life-saving interventions. Due to their invasive nature, CVADss are prone to complications such as infection, bacterial biofilm production, and catheter occlusion due to a thrombus. A CVAD is placed in up to 97% of patients in the intensive care unit, exposing this vulnerable population to risk of nosocomial infection and occlusion. Current standard of care involves use of normal saline (for CVCs and PICCs) or citrate (for hemodialysis catheters) as a catheter locking solution. CVAD complications remain a problem with current standard of care. 4% tetrasodium Ethylenediaminetetraacetic acid (EDTA) fluid (KiteLock Sterile Locking Solution) possesses antimicrobial, anti-biofilm, and anti-thrombotic properties and is approved by Health Canada as a catheter locking solution. As such, it may be superior CVC locking solution than the present normal saline or citrate lock. To our knowledge, the efficacy of an EDTA catheter locking solution has not yet been investigated in the intensive care patient population. Our team proposes to fill this knowledge gap by performing a multi-centre, cluster-randomized, crossover study evaluating the impact of KiteLock Sterile Locking Solution on a primary composite outcome of CLABSI, intraluminal occlusion, and alteplase use in the ICU of six ICU's compared to the standard of care saline lock.
Status | Recruiting |
Enrollment | 1524 |
Est. completion date | December 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - >18 years of age ICU/HAU Admission - Presence of a central venous catheter requiring locking. This includes CVCs, IVADs, dialysis lines, and PICC lines. Exclusion Criteria: - Known or tested sensitivity to EDTA or edetate - Confirmed or suspected pregnancy - Patients who decline receiving blood products - Physician, patient, or temporary substitute decision maker (TSDM) declines - Currently enrolled in any other research study that may confound primary outcome measures. Co-enrollment in multiple studies will be considered on an individual basis - Patients who were previously enrolled in the study. Patients who were enrolled in the first period are not eligible for (re-)enrolment in the second period, and patients who are enrolled in the study and transferred to another participating hospital are not eligible for (re-)enrollment at the receiving hospital. Patients who had been discharged from the unit to another hospital ward and are re-admitted to the critical care unit are no eligible for re-enrollment into the study. |
Country | Name | City | State |
---|---|---|---|
Canada | Burnaby Hospital | Burnaby | British Columbia |
Canada | Nanaimo Regional General Hospital | Nanaimo | British Columbia |
Canada | Royal Columbian Hospital | New Westminster | British Columbia |
Canada | Surrey Memoral Hospital | Surrey | British Columbia |
Canada | Royal Jubilee Hospital | Victoria | British Columbia |
Canada | St. Boniface Hospital | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
Fraser Health | Center for Health Evaluation & Outcome Services, SterileCare Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Subgroup analysis | Those with their CVAD in place for 7 days or more will be analyzed in a separate subgroup for primary and secondary outcomes | From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months | |
Primary | Primary Composite Outcome of CVAD Complications Modifiable by Lock Procedures | incidence rate of the following: catheter obstruction requiring Alteplase, central-line associated bloodstream infection (CLABSI), or CVC replacement due to occlusion. | From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months. | |
Secondary | Incidence rate of confirmed/suspected CLABSI | Confirmed diagnosis of CLABSI as diagnosed by the patients healthcare team and on the patient chart. | From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months | |
Secondary | Incidence rate of catheter occlusion requiring removal | Confirmed occurrence of occlusion requiring removal as noted by the patients healthcare team and on the patient chart. | From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months | |
Secondary | Incidence rate of catheter obstruction requiring alteplase use | Confirmed obstruction requiring alteplase use as noted by the patients healthcare team and on the patient chart. | From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months | |
Secondary | Direct cost related to alteplase use for catheter occlusion | This outcome will be evaluated based on economical analysis. | through study From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months, an average of 16 months | |
Secondary | Incidence rate of catheter-associated venous thrombosis | Confirmed occurrence of catheter-associated venous thrombosis as noted by the patients healthcare team and on the patient chart. | From date of randomization until the date of ICU discharge, patient death death, or through study completion, an average of 9 months | |
Secondary | Incidence rate of catheter colonization | Confirmed occurrence of catheter colonization as noted by the patients healthcare team and on the patient chart. | From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months | |
Secondary | Classification of microbial species isolated from colonized catheters | A convenience sample of 15 colonized CVC's and 15 non-colonized CVC's (control) will be collected for further analysis as available. | From date of randomization until the date of catheter removal, ICU discharge, patient death death, or through study completion, an average of 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04054128 -
Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients
|
Phase 4 | |
Recruiting |
NCT05729321 -
Lock sOlutiOnS for Epicutaneo-caval Catheters in Neonates: a "LOOSEN" Pilot Study
|
||
Recruiting |
NCT05334225 -
Assessing the Knowledge and Self-confidence of Healthcare Workers to Perform Transurethral Catheterization: A Multicenter Survey
|
||
Completed |
NCT06106659 -
Comparison of Clinical Outcomes of Mini Midline Catheters With Different Placement Sites: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT03655106 -
Ultrasound Guided Catheter Length Survivability
|
N/A | |
Not yet recruiting |
NCT06014099 -
Research on the Application of Blood Collection Through Midline Catheters of Different Lengths
|
N/A | |
Completed |
NCT03693755 -
Dislocation Rates of Femoral Catheter Placed Sonographically Either In-plane or Out-of-plane
|
N/A | |
Not yet recruiting |
NCT06019897 -
Impact of Tubing Colonization on the Incidence of Central Venous Catheter Infection
|
||
Not yet recruiting |
NCT06149533 -
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
|
Phase 3 | |
Completed |
NCT01465594 -
Study Comparing Urinary Diversion (Transurethral/Suprapubic) After Radical Prostatectomy
|
N/A | |
Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A | |
Completed |
NCT04569474 -
Peripheral IV Dressing and Phlebitis in Patients From Amazon
|
N/A | |
Completed |
NCT05814887 -
Reduction of Mechanical IV Complication Using a New Medical Device
|
N/A | |
Recruiting |
NCT05741866 -
Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs)
|
N/A | |
Completed |
NCT06312215 -
Effect Of Open And Closed System Peripheral Catheters Used In Pediatric Services
|
N/A | |
Recruiting |
NCT04359056 -
Clinical Pharmacy for Patients With a PICC Line
|
N/A | |
Not yet recruiting |
NCT05869877 -
The PIV5Rights Safety and Quality Bundle
|
N/A | |
Completed |
NCT04285775 -
A Novel Device for Surveillance of Vascular Access Sites for Bleeding
|
||
Completed |
NCT05446987 -
Position Change and Back Massage Versus Early Ambulation on Post Transfemoral Coronary Angiography Complications
|
N/A | |
Not yet recruiting |
NCT05354921 -
Indwelling vs Intermittent Catheterization Pilot Study
|
N/A |